CytoDyn Inc. (CYDY) Stock Analysis
Over the past 10 years, CytoDyn (CYDY) earnings per share (EPS) grew 8.7% a year, revenue grew 100.0% a year (over 1 year) and free cash flow grew 3.0% a year, with an average return on invested capital (ROIC) of -403.8%. CYDY stock trades at $0.20.
CytoDyn Inc. functions as a biotechnology enterprise currently in its clinical development phase. The company primarily concentrates on crafting therapies for a variety of medical conditions, leveraging leronlimab – an innovative humanized monoclonal antibody designed to interact with the CCR5 receptor.
Exhibit A Growth Dossier
| Metric | 10yr | 5yr | 1yr | Grade |
|---|---|---|---|---|
| Book Value/Share GrowthBV/S Still negative | -18.0% | -27.6% | -3.9% | F |
| EPS GrowthEPS Still negative | 8.7% | 17.7% | -1473.7% | F |
| Revenue GrowthRevenue | — | — | 100.0% | B+ |
| Cash Flow GrowthCash Flow Still negative | 3.0% | 17.1% | -96.8% | F |
| ROICROIC | -403.8% | 76.6% | 78.7% | F |
Exhibit B Valuation Ledger
- Current EPS
- -$0.03
- Historical Avg P/E
- 109.1
- Future P/E (used for sticker price)
- Projected EPS (10yr)
- Sticker Price (10yr)
- Price for 15% Annual Return
- Expected Annual Return
No card required. $5/month after the trial if you keep going.
Not investment advice — a structured read of historical fundamentals, not a forecast or recommendation. Always do your own research.
Exhibit C Raw Data (last 10 years)
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Book Value / ShareBV/S | $0.11 | -$0.01 | -$0.08 | -$0.03 | -$0.01 | -$0.04 | -$0.14 | -$0.13 | -$0.12 | -$0.08 | -$0.09 | -$0.08 | |
| Basic EPSEPS | -$0.27 | -$0.19 | -$0.28 | -$0.21 | -$0.34 | -$0.30 | -$0.43 | -$0.10 | -$0.05 | $0.00 | -$0.03 | -$0.03 | |
| RevenueRevenue | $0 | $0 | $0 | $0 | $0 | $0 | $266,000 | $0 | $0 | $-5,916,000 | $0 | $0 | |
| Free Cash FlowCash Flow | $-24,822,600 | $-26,743,582 | $-29,897,971 | $-50,511,448 | $-68,844,710 | $-117,695,000 | $-77,723,000 | $-25,110,000 | $-10,982,000 | $-8,765,000 | $-17,252,000 | $-17,252,000 | |
| ROIC (%)ROIC | -207.0% | -920.2% | 374.9% | -3067.0% | -562.1% | -246.4% | 252.4% | 54.9% | 41.9% | -45.1% | 78.7% | — |
The exact underlying data used to compute the growth rates and grades above. The highlighted TTM column is the trailing twelve months through the most recently reported quarter.
Ticker INVESTigator Price Target
Analyst Data
Price Target
2 firms rate it — 1 buy, 1 hold · No target published in the last 12 months
CYDY Stock FAQ
Do analysts rate CYDY a buy?
Opinion is mixed. Of 2 firms covering CytoDyn, the ratings are 1 buy or strong buy, 1 hold and 0 sell or strong sell.
How fast is CytoDyn growing?
Annual growth rates for CYDY. EPS: 8.7% over 10 years, 17.7% over 5 years, -1473.7% over 1 year. Revenue: 100.0% over 1 year. Free cash flow: 3.0% over 10 years, 17.1% over 5 years, -96.8% over 1 year. Book value per share: -18.0% over 10 years, -27.6% over 5 years, -3.9% over 1 year.
What is CYDY's ROIC?
CytoDyn's return on invested capital (ROIC) was 78.7% in fiscal 2026. Its 10-year average ROIC is -403.8%. ROIC above 10% is generally a sign of a business with a durable competitive advantage.
What is CYDY's P/E ratio?
CYDY has no meaningful P/E ratio right now because its earnings are negative. Trailing earnings per share are -$0.03.
What is CytoDyn's market cap and stock price?
CYDY last traded at $0.20 as of October 12, 2026. Its 52-week range is $0.18 to $0.40. CytoDyn has a market cap of $273.9M.
Exhibit D Related Coverage
Similar Stocks
Data as of October 12, 2026. Findings are derived from historical fundamentals — not a forecast, not advice. Cross-examine before you invest.
Grades are produced by Ticker INVESTigator's own model from public financial data and are for informational and educational purposes only. They are not investment advice or a recommendation to buy or sell any security. Do your own research.